EU/3/18/2106

Table of contents

About

On 14 December 2018, orphan designation (EU/3/18/2106) was granted by the European Commission to AudioCure Pharma GmbH, Germany, for 6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole for the treatment of sudden sensorineural hearing loss.

Key facts

Active substance
6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole
Disease / condition
Treatment of sudden sensorineural hearing loss
Date of decision
14/12/2018
Outcome
Positive
Orphan decision number
EU/3/18/2106

Sponsor's contact details

AudioCure Pharma GmbH
Schlegelstraße, 9
10115 Berlin
Germany
Tel. +49 (30) 221 8397 0
E-mail: info@audiocure.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating